glp 1 agonist medullary thyroid cancer Frontiers Semaglutide: What we know about

Glucagon-like peptide-1 (GLP-1) is an incretin hormone, one of several gut-derived peptides secreted in response to nutrient intake that promote insulin release

Order laboratory tests : Such as blood sugar levels, kidney and liver function tests, and possibly thyroid function

These two peptides (GLP-1 and GIP) potentiate glucose-stimulated insulin secretion in an additive manner, likely contribute equally to the incretin effect and together can fully account for the majority of the incretin effect in humans

Key Report Takeaways By drug, semaglutide led with 51.35% of the Latin America GLP-1 agonists market share in 2025, while tirzepatide is projected to record the fastest 12.12% CAGR through 2031

Phase 3 studies using mazdutide as obesity treatment in a Chinese population (doses between 4 and 9 mg) are also ongoing (NCT05607680, NCT06164873)